Guardant Health Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名27/208位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為111.24。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Guardant Health Inc評分
相關信息
行業排名
27 / 208
全市場排名
86 / 4563
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Guardant Health Inc亮點
亮點風險
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
公司代碼GH
公司Guardant Health Inc
CEOTalasaz (Amirali)
網址https://guardanthealth.com/
常見問題
Guardant Health Inc(GH)的當前股價是多少?
Guardant Health Inc(GH)的當前股價是 108.760。
Guardant Health Inc 的股票代碼是什麼?
Guardant Health Inc的股票代碼是GH。
Guardant Health Inc股票的52週最高點是多少?
Guardant Health Inc股票的52週最高點是113.910。
Guardant Health Inc股票的52週最低點是多少?
Guardant Health Inc股票的52週最低點是34.800。
Guardant Health Inc的市值是多少?
Guardant Health Inc的市值是13.60B。
Guardant Health Inc的淨利潤是多少?
Guardant Health Inc的淨利潤為-436.37M。
現在Guardant Health Inc(GH)的股票是買入、持有還是賣出?
根據分析師評級,Guardant Health Inc(GH)的總體評級為買入,目標價格為111.237。